Meeting
2022 ASCO Quality Care Symposium
Post-protocol therapies in first-line immunotherapy trials in non–small cell lung cancer (NSCLC).
Authors
Aakash Desai
Mayo Clinic Rochester, Rochester, MN
Aakash Desai, Aaron Scott Mansfield, Anuhya Kommalapati, Konstantinos Leventakos, Alex A. Adjei, Howard Jack West
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Access to Treatment
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 125)
DOI
10.1200/JCO.2022.40.28_suppl.125
Abstract #
125
Poster Bd #
D24
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2022 ASCO Annual Meeting
Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.
First Author: Kim Leitzel
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Association of immune microenvironment to response in treatment-naïve non-small cell lung cancer (NSCLC) samples with follow-up second-line immunotherapy data.
First Author: Marie Cumberbatch
Poster
2019 Genitourinary Cancers Symposium
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
First Author: Arlene O. Siefker-Radtke